aus finanznachrichten.de
Sona Nanotech Inc.: Sona Announces Commercial Agreement with Siva Therapeutics
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021, to its short form base prospectus dated March 31, 2021.
Halifax, Nova Scotia--(Newsfile Corp. - October 20, 2022) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has entered into an agreement to supply certain gold nanorod material to Siva Therapeutics, Inc. ("Siva"), a developer of advanced, 'in-vivo' therapies for treating cancer.
Siva Therapeutics' Targeted Hyperthermia cancer Therapy ("THT") is being developed to be an elegant, safe and effective cancer treatment that generates therapeutic heat within solid tumors using gold nanorods with an infrared light device. THT has multiple beneficial effects on tumors, and it is more selective than chemotherapy, less destructive than radiation, and without the risks of surgical treatment. The treatment is minimally invasive, reducing harmful side effects, and stimulates the immune system. In addition to being more affordable and more effective, this technology could deliver faster results than current cancer treatments. Siva's approach is to use gold nanorods and an infrared light device to destroy solid tumors with THT and improve patient health and outcomes. Siva has completed successful small animal studies for THT and is preparing to undertake large animal studies in 2023 before beginning human clinical trials for colorectal and possibly other cancer tumors. |
